UNDERWRITING AGREEMENTUnderwriting Agreement • October 9th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations • New York
The undersigned, Oasmia Pharmaceutical AB, a company formed under the laws of Sweden (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Oasmia Pharmaceutical AB, the “Company”), hereby confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which you are acting as Representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENTUnderwriting Agreement • October 21st, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations • New York
The undersigned, Oasmia Pharmaceutical AB, a company formed under the laws of Sweden (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Oasmia Pharmaceutical AB, the “Company”), hereby confirms its agreement (this “Agreement”) with Joseph Gunnar & Co., LLC and H.C. Wainwright & Co., LLC (hereinafter together referred to as “you” (including its correlatives) or the “Representatives”) and with the other underwriters named on Schedule 1 hereto for which you are acting as Representatives (the Representatives and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
RENTAL CONTRACT FOR SPACE Rental contract numberRental Contract • July 6th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
Space size and extent Retail space Level ㎡ Office space Level ㎡ Level ㎡ Storage space Level ㎡ Attic space Level ㎡ Basement space Level ㎡ Other space Level ㎡ 5 ca 880
RENTAL CONTRACT FOR SPACE Rental contract numberRental Contract • July 6th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
ADS WARRANT AGREEMENTWarrant Agreement • October 9th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations • New York
ADS WARRANT AGREEMENT (this “Warrant Agreement”) dated as of October __, 2015 (the “Issuance Date”) between Oasmia Pharmaceutical AB, a company incorporated under the laws of the Kingdom of Sweden (the “Company”), and The Bank of New York Mellon (the “Warrant Agent”).
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION MASTER MANUFACTURING AND SUPPLY AGREEMENTMaster Manufacturing and Supply Agreement • August 14th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This MASTER MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the 25th day of April, 2014 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
A NON EXCLUSIVE TOLL MANUFACTURING AGREEMENTToll Manufacturing Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations • Stockholm
This toll manufacturing agreement is made and entered into effective as of this 6th day of August 2013 (the “Effective Date”) by and between:
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • October 31st, 2017 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
Your loan agreementLoan Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
IN CONNECTION WITH THE PAYMENT OF THE NEW LOAN 1803-50-06819 IS REDEEMED AT THE SAME TIME AS THE EXISTING LOAN 1803-50-06614 WITH A DEBT OF 20,000,000 SEK + ACCRUED INTEREST, DEBT + INTEREST IS DEBITED FROM ACCOUNT NUMBER 502285-0
FIRST AMENDMENT TO DISTRIBUTION AGREEMENT BETWEEN OASMIA PHARMACEUTICAL AB AND ABBOTT LABORATORIESDistribution Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This First Amendment (“First Amendment”) to the Distribution Agreement, dated as of July 8, 2009, between Abbott Laboratories, an Illinois corporation (“Abbott”), and Oasmia Pharmaceutical AB, a Swedish corporation (“Oasmia”) (the “Original Agreement”), is effective as of December ___, 2012 (“First Amendment Effective Date”). Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Original Agreement.
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This Commercial MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the ______ day of _____, 2011 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION COMMERCIAL PRODUCT ADDENDUM For DOXOPHOSCommercial Product Addendum • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
THIS COMMERCIAL PRODUCT ADDENDUM is an addendum to that certain Master Manufacturing and Supply Agreement of the 25th of April, 2014 by and between BAXTER ONCOLOGY GMBH (“Baxter”), a German company having a place of business at Kantstrasse 2, 33790 Halle / Westphalia, Germany, and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (the “Commercial Supply Agreement”) and shall commence on the 20th day of May, 2014 (“Commercial Product Addendum Effective Date”) and expire at the end of 19th day of May 2019 (the “Commercial Product Addendum Term”).
STOCK lENDING AgreementStock Lending Agreement • September 16th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION COMMERCIAL PRODUCT ADDENDUM For DOXOPHOSCommercial Product Addendum • August 14th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
THIS COMMERCIAL PRODUCT ADDENDUM is an addendum to that certain Master Manufacturing and Supply Agreement of the 25th of April, 2014 by and between BAXTER ONCOLOGY GMBH (“Baxter”), a German company having a place of business at Kantstrasse 2, 33790 Halle / Westphalia, Germany, and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (the “Commercial Supply Agreement”) and shall commence on the 20th day of May, 2014 (“Commercial Product Addendum Effective Date”) and expire at the end of 19th day of May 2019 (the “Commercial Product Addendum Term”).
This Supply and Exclusive License Agreement is made between Oasmia Pharmaceutical AB (“Licensor”) a corporation under the laws of Sweden and having its principal office at Vallongatan 1, 752 28 Uppsala, Sweden And Medison Pharma LTD (“Licensee”) a...Supply and Exclusive License Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
- Licensor has certain worldwide rights to Licensed Technology (hereinafter defined) to the Product (hereinafter defined).
This Development, Supply and Exclusive License Agreement is made between Oasmia Pharmaceutical AB (“Licensor”) a corporation organized under the laws of Sweden and having its principal office at Vallongatan 1, 752 28 Uppsala, Sweden and Nippon Zenyaku...Development, Supply and Exclusive License Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations • England
- Licensor has certain worldwide rights to Licensed Technology (hereinafter defined) to a veterinary pharmaceutical product (hereinafter defined).
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • August 14th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This Commercial MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the 16th day of February, 2011 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION SALE AND PURCHASE AGREEMENTSale and Purchase Agreement • August 24th, 2017 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
DISTRIBUTION AGREEMENTDistribution Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations • New York
WHEREAS, Abbott is engaged, directly and through its Affiliates in the business of developing, producing and selling, among other things, veterinary pharmaceutical products;
